The Benefits of Utilizing Continuous Glucose Monitoring of Diabetes Mellitus in Primary Care: A Systematic Review.
continuous glucose monitor (CGM)
flash glucose monitor (FGM)
primary care
systematic review
type 1 diabetes
type 2 diabetes
Journal
Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
3
5
2023
pubmed:
2
2
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Continuous glucose monitoring (CGM) and intermittently scanned CGM (is-CGM) have shown to effectively manage diabetes in the specialty setting, but their efficacy in the primary care setting remains unknown. Does CGM/is-CGM improve glycemic control, decrease rates of hypoglycemia, and improve staff/physician satisfaction in primary care? If so, what subgroups of patients with diabetes are most likely to benefit? A comprehensive search in seven databases was performed in June 2021 for primary studies examining any continuous glucose monitoring system in primary care. We excluded studies with fewer than 20 participants, specialty care only, or hospitalized participants. The National Heart, Lung and Blood Institute and Grading of Recommendations Assessment, Development and Evaluation were used for the quality assessment. The weighted mean difference (WMD) of HbA1c between CGM/is-CGM and usual care with 95% confidence interval was calculated. A narrative synthesis was conducted for change of time in, above, or below range (TIR, TAR, and TBR) hypoglycemic events and staff/patient satisfaction. From ten studies and 4006 participants reviewed, CGM was more effective at reducing HbA1c compared with usual care (WMD -0.43%). There is low certainty of evidence that CGM/is-CGM improves TIR, TAR, or TBR over usual care. The CGM can reduce hypoglycemic events and staff/patient satisfaction is high. Patients with intensive insulin therapy may benefit more from CGM/is-CGM. Compared with usual care, CGM/is-CGM can reduce HbA1c, but most studies had notable biases, were short duration, unmasked, and were sponsored by industry. Further research needs to confirm the long-term benefits of CGM/is-CGM in primary care.
Sections du résumé
BACKGROUND
Continuous glucose monitoring (CGM) and intermittently scanned CGM (is-CGM) have shown to effectively manage diabetes in the specialty setting, but their efficacy in the primary care setting remains unknown. Does CGM/is-CGM improve glycemic control, decrease rates of hypoglycemia, and improve staff/physician satisfaction in primary care? If so, what subgroups of patients with diabetes are most likely to benefit?
METHODS
A comprehensive search in seven databases was performed in June 2021 for primary studies examining any continuous glucose monitoring system in primary care. We excluded studies with fewer than 20 participants, specialty care only, or hospitalized participants. The National Heart, Lung and Blood Institute and Grading of Recommendations Assessment, Development and Evaluation were used for the quality assessment. The weighted mean difference (WMD) of HbA1c between CGM/is-CGM and usual care with 95% confidence interval was calculated. A narrative synthesis was conducted for change of time in, above, or below range (TIR, TAR, and TBR) hypoglycemic events and staff/patient satisfaction.
RESULTS
From ten studies and 4006 participants reviewed, CGM was more effective at reducing HbA1c compared with usual care (WMD -0.43%). There is low certainty of evidence that CGM/is-CGM improves TIR, TAR, or TBR over usual care. The CGM can reduce hypoglycemic events and staff/patient satisfaction is high. Patients with intensive insulin therapy may benefit more from CGM/is-CGM.
CONCLUSIONS
Compared with usual care, CGM/is-CGM can reduce HbA1c, but most studies had notable biases, were short duration, unmasked, and were sponsored by industry. Further research needs to confirm the long-term benefits of CGM/is-CGM in primary care.
Identifiants
pubmed: 35100891
doi: 10.1177/19322968211070855
pmc: PMC10210096
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
762-774Références
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
J Manag Care Spec Pharm. 2020 May;26(5):600-609
pubmed: 32347180
Diabetes Care. 2017 Nov;40(11):1425-1432
pubmed: 28801473
Circulation. 2007 Jul 10;116(2):151-7
pubmed: 17576864
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
J Clin Endocrinol Metab. 2014 Sep;99(9):3112-21
pubmed: 24940655
Prim Care Diabetes. 2021 Apr;15(2):199-207
pubmed: 33257275
Endocr Pract. 2021 Jun;27(6):505-537
pubmed: 34116789
J Diabetes Sci Technol. 2007 Jul;1(4):511-21
pubmed: 19885114
Diab Vasc Dis Res. 2019 Jul;16(4):385-395
pubmed: 31271312
Diabetes Care. 2011 Oct;34(10):2237-43
pubmed: 21949221
Adv Ther. 2019 Mar;36(3):579-596
pubmed: 30659511
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Fam Pract Manag. 2021 Mar-Apr;28(2):7-14
pubmed: 33687183
Diabetes Care. 2006 Jan;29(1):44-50
pubmed: 16373894
N Engl J Med. 2008 Oct 2;359(14):1464-76
pubmed: 18779236
J Epidemiol Glob Health. 2020 Mar;10(1):107-111
pubmed: 32175717
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
BMC Endocr Disord. 2021 Apr 23;21(1):79
pubmed: 33888117
Am Fam Physician. 2020 Jun 1;101(11):646
pubmed: 32463633
Diabetes Technol Ther. 2018 Sep;20(9):613-621
pubmed: 30095980
Mayo Clin Proc. 2010 Dec;85(12 Suppl):S3-4
pubmed: 21106869
BMC Endocr Disord. 2018 Jul 21;18(1):47
pubmed: 30031385
Diabetes Spectr. 2018 Aug;31(3):279-287
pubmed: 30140145
JAMA. 2017 Jan 24;317(4):371-378
pubmed: 28118453
Postgrad Med. 2020 May;132(4):305-313
pubmed: 32223687
J Diabetes Sci Technol. 2022 Mar;16(2):383-389
pubmed: 32935561
N Engl J Med. 2014 Apr 17;370(16):1514-23
pubmed: 24738668
Diabetes Care. 2021 Jan;44(Suppl 1):S85-S99
pubmed: 33298418
Diabetologia. 2019 Jan;62(1):3-16
pubmed: 30171279
Lancet Diabetes Endocrinol. 2020 Jan;8(1):17-26
pubmed: 31862147
Diabetes Res Clin Pract. 2014 Nov;106(2):247-55
pubmed: 25271117
Diabetes Technol Ther. 2008 Oct;10(5):377-83
pubmed: 18715214
Diabetes Metab Res Rev. 2021 Jan;37(1):e3355
pubmed: 32469094
Postgrad Med. 2017 Nov;129(8):781-790
pubmed: 28945141
J Diabetes Sci Technol. 2021 May;15(3):539-545
pubmed: 33719598
Diabetes Care. 2020 May;43(5):1146-1156
pubmed: 32312858